Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Insulin detemir may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Levemir® is a modern insulin (insulin analogue) with a long-acting effect. Modern insulin products are improved versions of human insulin. Levemir® is used to reduce the high blood sugar level in adults, adolescents and children aged 1 year and above with diabetes mellitus (diabetes). Diabetes is a disease where your body does not produce enough insulin to control the level of your blood sugar. Levemir® can be used with meal-related rapid acting insulin medicines. In treatment of type 2 diabetes mellitus, Levemir® may also be used in combination with tablets for diabetes and/or with injectable anti-diabetic products, other than insulin. Levemir® has a long and steady blood-sugar-lowering action within 3 to 4 hours after injection. Levemir® provides up to 24 hours of basal insulin coverage. 2.
e Levemir®
Do not use Levemir® ► ► ► ► ► ►
If you are allergic to insulin detemir or any of the other ingredients in this medicine, see section 6, Contents of the pack and other information. If you suspect hypoglycaemia (low blood sugar) is starting, see a) Summary of serious and very common side effects in section 4. In insulin infusion pumps. If FlexPen® is dropped, damaged or crushed. If it has not been stored correctly or been frozen, see section 5, How to store Levemir®. If the insulin does not appear water clear, colourless and aqueous.
If any of these applies, do not use Levemir®. Talk to your doctor, nurse or pharmacist for advice. Before using Levemir® ► ► ► ►
Check the label to make sure it is the right type of insulin. Always use a new needle for each injection to prevent contamination. Needles and Levemir® FlexPen® must not be shared. Levemir® FlexPen® is only suitable for injecting under the skin. Speak to your doctor if you need to inject your insulin by another method.
Warnings and precautions Some conditions and activities can affect your need for insulin. Consult your doctor: ► If you have trouble with your kidneys or liver, or with your adrenal, pituitary or thyroid glands. ► If you exercise more than usual or if you want to change your usual diet, as this may affect your blood sugar level. ► If you are ill, carry on taking your insulin and consult your doctor. ► If you are going abroad, travelling over time zones may affect your insulin needs and the timing of your injections. ► If you have very low albumin you need to carefully monitor your blood sugar level. Discuss this with your doctor. Skin changes at the injection site The injection site should be rotated to help prevent changes to the fatty tissue under the skin, such as skin thickening, skin shrinking or lumps under the skin. The insulin may not work very well if you inject into a lumpy, shrunken or thickened area (see section 3, How to use Levemir®). Tell your doctor if you notice any skin changes at the injection site. Tell your doctor if you are currently injecting into these affected areas before you start injecting in a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose. Children and adolescents Levemir® can be used in adolescents and children aged 1 year and above. The safety and efficacy of Levemir® in children below 1 year of age have not been established. No data are available. Other medicines and Levemir® Tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines. Some medicines affect your blood sugar level and this may mean that your insulin dose has to change. Listed below are the most common medicines which may affect your insulin treatment. Your blood sugar level may fall (hypoglycaemia) if you take: • Other medicines for the treatment of diabetes • Monoamine oxidase inhibitors (MAOI) (used to treat depression) • Beta-blockers (used to treat high blood pressure) • Angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure) • Salicylates (used to relieve pain and lower fever) • Anabolic steroids (such as testosterone) • Sulphonamides (used to treat infections).
Your blood sugar level may rise (hyperglycaemia) if you take: • Oral contraceptives (birth control pills) • Thiazides (used to treat high blood pressure or excessive fluid retention) • Glucocorticoids (such as 'cortisone' used to treat inflammation) • Thyroid hormones (used to treat thyroid gland disorders) • Sympathomimetics (such as epinephrine [adrenaline], or salbutamol, terbutaline used to treat asthma) • Growth hormone (medicine for stimulation of skeletal and somatic growth and pronounced influence on the body's metabolic processes) • Danazol (medicine acting on ovulation). Octreotide and lanreotide (used for treatment of acromegaly, a rare hormonal disorder that usually occurs in middle-aged adults, caused by the pituitary gland producing excess growth hormone) may either increase or decrease your blood sugar level. Beta-blockers (used to treat high blood pressure) may weaken or suppress entirely the first warning symptoms which help you to recognise low blood sugar. Pioglitazone (tablets used for the treatment of type 2 diabetes) Some patients with long-standing type 2 diabetes and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema). If you have taken any of the medicines listed here, tell your doctor, nurse or pharmacist. Drinking alcohol and taking Levemir® ►
If you drink alcohol, your need for insulin may change as your blood sugar level may either rise or fall. Careful monitoring is recommended.
Pregnancy and breast-feeding ►
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your insulin dose may need to be changed during pregnancy and after delivery. Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby. ► If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses. Ask your doctor, nurse or pharmacist for advice before taking any medicine while pregnant or breastfeeding. Driving and using machines ► • •
Please ask your doctor whether you can drive a car or operate a machine: If you have frequent hypoglycaemia. If you find it hard to recognise hypoglycaemia.
If your blood sugar is low or high, it might affect your concentration and ability to react and therefore also your ability to drive a car or operate a machine. Bear in mind that you could endanger yourself or others. Important information about some of the ingredients in Levemir®
Levemir® contains less than 1 mmol sodium (23 mg) per dose, i.e. Levemir® is essentially 'sodiumfree'. 3.
Levemir®
Dose and when to take your insulin Always use your insulin and adjust your dose exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure. Levemir® can be used with meal-related rapid acting insulin medicines. In treatment of type 2 diabetes mellitus, Levemir® may also be used in combination with tablets for diabetes and/or with injectable anti-diabetic products, other than insulin. Do not change your insulin unless your doctor tells you to. Your dose may have to be adjusted by your doctor if: • your doctor has switched you from one type or brand of insulin to another, or • your doctor has added another medicine for the treatment of diabetes, in addition to your Levemir® treatment. Use in children and adolescents Levemir® can be used in adolescents and children aged 1 year and above. There is no experience with the use of Levemir® in children below the age of 1 year. Use in special patient groups If you have reduced kidney or liver function, or if you are above 65 years of age, you need to check your blood sugar more regularly and discuss changes in your insulin dose with your doctor. How often to inject When Levemir® is used in combination with tablets for diabetes and/or in combination with injectable anti-diabetic products, other than insulin, Levemir® should be administered once a day. When Levemir® is used as part of a basal-bolus insulin regimen Levemir® should be administered once or twice daily depending on patients' needs. Dose of Levemir® should be adjusted individually. The injection can be given at any time during the day, but at the same time each day. For patients who require twice daily dosing to optimise blood sugar control, the evening dose can be administered in the evening or at bedtime. How and where to inject Levemir® is for injection under the skin (subcutaneously). You must never inject Levemir® directly into a vein (intravenously) or muscle (intramuscularly). Levemir® FlexPen® is only suitable for injecting under the skin. Speak to your doctor if you need to inject your insulin by another method. With each injection, change the injection site within the particular area of skin that you use. This may reduce the risk of developing lumps or skin pitting (see section 4, Possible side effects). The best places to give yourself an injection are: the front of your thighs, the front of your waist (abdomen), or the upper arm. You should always measure your blood sugar regularly. How to handle Levemir® FlexPen®
Levemir® FlexPen® is a pre-filled, colour-coded, disposable pen containing insulin detemir. Read carefully the instructions for use included in this package leaflet. You must use the pen as described in the Instructions for use. Always ensure you use the correct pen before you inject your insulin. If you take more insulin than you should If you take too much insulin your blood sugar gets too low (hypoglycaemia). See a) Summary of serious and very common side effects in section 4. If you forget to take your insulin If you forget to take your insulin your blood sugar may get too high (hyperglycaemia). See c) Effects from diabetes in section 4. If you stop taking your insulin Do not stop taking your insulin without speaking with a doctor, who will tell you what needs to be done. This could lead to very high blood sugar (severe hyperglycaemia) and ketoacidosis. See c) Effects from diabetes in section 4. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. a)
Summary of serious and very common side effects
Low blood sugar (hypoglycaemia) is a very common side effect. It may affect more than 1 in 10 people. Low blood sugar may occur if you: • Inject too much insulin. • Eat too little or miss a meal. • Exercise more than usual. • Drink alcohol (see section 2 Drinking alcohol and taking Levemir®). Signs of low blood sugar: Cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating. Severe low blood sugar can lead to unconsciousness. If prolonged severe low blood sugar is not treated, it can cause brain damage (temporary or permanent) and even death. You may recover more quickly from unconsciousness with an injection of the hormone glucagon given by someone who knows how to use it. If you are given glucagon you will need glucose or a sugar snack as soon as you are conscious. If you do not respond to glucagon treatment, you will have to be treated in a hospital. What to do if you experience low blood sugar: ► If you experience low blood sugar, eat glucose tablets or another high sugar snack (e.g. sweets, biscuits, fruit juice). Measure your blood sugar if possible and rest. Always carry glucose tablets
► ►
or high sugar snacks with you, just in case. When the symptoms of low blood sugar have disappeared or when your blood sugar level is stabilised, continue insulin treatment as usual. If you have such low blood sugar that makes you pass out, if you have had the need for an injection of glucagon, or if you have experienced many incidents of low blood sugar, talk to a doctor. The amount or timing of insulin, food or exercise may need to be adjusted.
Tell relevant people that you have diabetes and what the consequences may be, including the risk of passing out (becoming unconscious) due to low blood sugar. Let them know that if you pass out, they must turn you on your side and get medical help straight away. They must not give you any food or drink because you may choke. Serious allergic reaction to Levemir® or one of its ingredients (called a systemic allergic reaction) is a very rare side effect but can potentially be life threatening. It may affect less than 1 in 10,000 people. Seek medical advice immediately: • If signs of allergy spread to other parts of your body. • If you suddenly feel unwell, and you: start sweating; start being sick (vomiting); have difficulty in breathing; have a rapid heartbeat; feel dizzy. ► If you notice any of these signs, seek medical advice immediately. Skin changes at the injection site: If you inject insulin at the same place, the fatty tissue may shrink (lipoatrophy) or thicken (lipohypertrophy) (may affect less than 1 in 100 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis; how often this occurs is not known). The insulin may not work very well if you inject into a lumpy, shrunken or thickened area. Change the injection site with each injection to help prevent these skin changes. b)
List of other side effects
Uncommon side effects May affect less than 1 in 100 people. Signs of allergy: Local allergic reactions (pain, redness, hives, inflammation, bruising, swelling and itching) at the injection site may occur. These usually disappear after a few weeks of taking your insulin. If they do not disappear, or if they spread throughout your body, talk to your doctor immediately. See also Serious allergic reaction above. Vision problems: When you first start your insulin treatment, it may disturb your vision, but the disturbance is usually temporary. Swollen joints: When you start taking insulin, water retention may cause swelling around your ankles and other joints. Normally this soon disappears. If not, contact your doctor. Diabetic retinopathy (an eye disease related to diabetes which can lead to loss of vision): If you have diabetic retinopathy and your blood sugar level improves very fast, the retinopathy may get worse. Ask your doctor about this. Rare side effects May affect less than 1 in 1,000 people. Painful neuropathy (pain due to nerve damage): If your blood sugar level improves very fast, you may get nerve related pain, this is called acute painful neuropathy and is usually transient. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side
effects not listed in this leaflet. You can also report side effects directly via Great Britain Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store By reporting side effects you can help provide more information on the safety of this medicine. c)
Effects from diabetes
High blood sugar (hyperglycaemia) High blood sugar may occur if you: • Have not injected enough insulin. • Forget to take your insulin or stop taking insulin. • Repeatedly take less insulin than you need. • Get an infection and/or a fever. • Eat more than usual. • Exercise less than usual. Warning signs of high blood sugar: The warning signs appear gradually. They include: increased urination; feeling thirsty; losing your appetite; feeling sick (nausea or vomiting); feeling drowsy or tired; flushed; dry skin; dry mouth and a fruity (acetone) smell of the breath. What to do if you experience high blood sugar: ► If you get any of above signs: test your blood sugar level, test your urine for ketones if you can, then seek medical advice immediately. ► These may be signs of a very serious condition called diabetic ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). If you do not treat it, this could lead to diabetic coma and eventually death. 5.
Levemir®
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the FlexPen® label and carton after 'EXP'. The expiry date refers to the last day of that month. Always keep the pen cap on your FlexPen® when you are not using it in order to protect it from light. Levemir® must be protected from excessive heat and light. Before opening: Levemir® FlexPen® that is not being used is to be stored in the refrigerator at 2°C to 8°C, away from the cooling element. Do not freeze. During use or when carried as a spare: You can carry your Levemir® FlexPen® with you and keep it at a temperature below 30°C or in a refrigerator (2°C to 8°C) for up to 6 weeks. If refrigerated, keep away from the cooling element. Do not freeze. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Levemir® contains • •
The active substance is insulin detemir. Each ml contains 100 units of insulin detemir. Each prefilled pen contains 300 units of insulin detemir in 3 ml solution for injection. 1 unit insulin detemir corresponds to 1 international unit of human insulin. The other ingredients are glycerol, phenol, metacresol, zinc acetate, disodium phosphate dihydrate, sodium chloride, hydrochloric acid, sodium hydroxide and water for injections.
What Levemir® looks like and contents of the pack Levemir® is presented as a solution for injection. Pack sizes of 1 (with or without needles), 5 (without needles) and 10 (without needles) pre-filled pens of 3 ml. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark Manufacturer The manufacturer can be identified by the batch number printed on the slip of the carton and on the label: –
If the second and third characters are S6, P5, K7, R7, VG, FG or ZF, the manufacturer is Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark.
–
If the second and third characters are H7 or T6, the manufacturer is Novo Nordisk Production SAS, 45 Avenue d'Orléans, F-28000 Chartres, France.
Now turn over for information on how to use your FlexPen®. This leaflet was last revised in 09/2022
Levemir®, FlexPen®, NovoFine® and NovoTwist® are trademarks owned by Novo Nordisk A/S, Denmark © 2022 Novo Nordisk A/S
Instructions on how to use LEVEMIR® solution for injection in a FlexPen® Read the following instructions carefully before using your FlexPen®. If you do not follow the instructions carefully, you may get too little or too much insulin, which can lead to too high or too low blood sugar level. Your FlexPen® is a pre-filled dial-a-dose insulin pen. You can select doses from 1 to 60 units in increments of 1 unit. FlexPen® is designed to be used with NovoFine® or NovoTwist® disposable needles up to a length of 8 mm. As a precautionary measure, always carry a spare insulin delivery device in case your FlexPen® in use is lost or damaged. Levemir® FlexPen® Pen cap
Cartridge
Residual scale
Pointer
Dose selector Pushbutton
Needle (example) Big outer needle cap
Inner needle cap
Needle
Paper tab
Caring for your pen Your FlexPen® must be handled with care. If it is dropped, damaged or crushed, there is a risk of insulin leakage. This may cause inaccurate dosing, which can lead to too high or too low blood sugar level. You can clean the exterior of your FlexPen® by wiping it with a medicinal swab. Do not soak it, wash or lubricate it as it may damage the pen. Do not refill your FlexPen®. Preparing your Levemir® FlexPen® Check the name and coloured label of your pen to make sure that it contains the correct type of insulin. This is especially important if you take more than one type of insulin. If you take the wrong type of insulin, your blood sugar level may get too high or too low. A Pull off the pen cap. A
B Remove the paper tab from a new disposable needle. Screw the needle straight and tightly onto your FlexPen®. B
C Pull off the big outer needle cap and keep it for later. C
D Pull off the inner needle cap and dispose of it. Never try to put the inner needle cap back on the needle. You may stick yourself with the needle. D
Always use a new needle for each injection. This reduces the risk of contamination, infection, leakage of insulin, blocked needles and inaccurate dosing. Be careful not to bend or damage the needle before use. Checking the insulin flow Prior to each injection small amounts of air may collect in the cartridge during normal use. To avoid injection of air and ensure proper dosing: E Turn the dose selector to select 2 units. E
2 units selected
F Hold your FlexPen® with the needle pointing upwards and tap the cartridge gently with your finger a few times to make any air bubbles collect at the top of the cartridge. F
G Keeping the needle upwards, press the push-button all the way in. The dose selector returns to 0. A drop of insulin should appear at the needle tip. If not, change the needle and repeat the procedure no more than 6 times.
If a drop of insulin still does not appear, the pen is defective, and you must use a new one. G
Always make sure that a drop appears at the needle tip before you inject. This makes sure that the insulin flows. If no drop appears, you will not inject any insulin, even though the dose selector may move. This may indicate a blocked or damaged needle. Always check the flow before you inject. If you do not check the flow, you may get too little insulin or no insulin at all. This may lead to too high blood sugar level. Selecting your dose Check that the dose selector is set at 0. H Turn the dose selector to select the number of units you need to inject. The dose can be corrected either up or down by turning the dose selector in either direction until the correct dose lines up with the pointer. When turning the dose selector be careful not to push the pushbutton as insulin will come out. You cannot select a dose larger than the number of units left in the cartridge. H
5 units selected
24 units selected
Always use the dose selector and the pointer to see how many units you have selected before injecting the insulin. Do not count the pen clicks. If you select and inject the wrong dose, your blood sugar level may get too high or too low. Do not use the residual scale, it only shows approximately how much insulin is left in your pen. Making the injection Insert the needle into your skin. Use the injection technique shown by your doctor or nurse. I Inject the dose by pressing the push-button all the way in until 0 lines up with the pointer. Be careful only to push the push-button when injecting.
Turning the dose selector will not inject insulin. I
J Keep the push-button fully depressed and let the needle remain under the skin for at least 6 seconds. This will make sure you get the full dose. Withdraw the needle from the skin then release the pressure on the push-button. Always make sure that the dose selector returns to 0 after the injection. If the dose selector stops before it returns to 0, the full dose has not been delivered, which may result in too high blood sugar level. J
K Lead the needle into the big outer needle cap without touching it. When the needle is covered, carefully push the big outer needle cap completely on and then unscrew the needle. Dispose of it carefully and put the pen cap back on your FlexPen®. K
Always remove the needle after each injection and store your FlexPen® without the needle attached. This reduces the risk of contamination, infection, leakage of insulin, blocked needles and inaccurate dosing. Further important information Caregivers must be very careful when handling used needles – to reduce the risk of needle sticks and cross-infection. Dispose of your used FlexPen® carefully without the needle attached. Never share your pen or your needles with other people. It might lead to cross-infection. Never share your pen with other people. Your medicine might be harmful to their health.
Always keep your pen and needles out of sight and reach of others, especially children.
Levemir FlexPen 100 units/ml solution for injection in pre-filled pen comes as injection containing 100iu. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Levemir FlexPen 100 units/ml solution for injection in pre-filled pen is insulin detemir.
Medicines with the same active substance, strength and form include: Levemir Penfill 100 units/ml solution for injection in cartridge. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Levemir FlexPen 100 units/ml solution for injection in pre-filled pen, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Levemir is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
Posology
The potency of insulin analogues, including insulin detemir, is expressed in units, whereas the potency of human insulin is expressed in international units. 1 unit insulin detemir corresponds to 1 international unit of human insulin.
Levemir can be used alone as the basal insulin or in combination with bolus insulin. It can also be used in combination with oral antidiabetic medicinal products and/or GLP-1 receptor agonists.
When Levemir is used in combination with oral antidiabetic medicinal products or when added to GLP-1 receptor agonists it is recommended to use Levemir once daily, initially at a dose of 0.1– 0.2 units/kg or of 10 units in adult patients. The dose of Levemir should be titrated based on the individual patient's needs.
When a GLP-1 receptor agonist is added to Levemir, it is recommended to reduce the dose of Levemir by 20% to minimise the risk of hypoglycaemia. Subsequently, dosage should be adjusted individually.
For individual dose adjustments, the following two titration guidelines are recommended for adults:
Adult type 2 diabetes titration guideline:
Average pre-breakfast SMPG*
Levemir dose adjustment
>10.0 mmol/l (180 mg/dl)
+8 units
9.1–10.0 mmol/l (163–180 mg/dl)
+6 units
8.1–9.0 mmol/l (145–162 mg/dl)
+4 units
7.1–8.0 mmol/l (127–144 mg/dl)
+2 units
6.1–7.0 mmol/l (109–126 mg/dl)
+2 units
4.1–6.0 mmol/l (73–108 mg/dl)
No change in dose (target)
If one SMPG measurement
3.1–4.0 mmol/l (56–72 mg/dl)
-2 units
<3.1 mmol/l (<56 mg/dl)
-4 units
*Self-Monitored Plasma Glucose
Adult type 2 diabetes simple self-titration guideline:
Average pre-breakfast SMPG*
Levemir dose adjustment
>6.1 mmol/l (>110 mg/dl)
+3 units
4.4–6.1 mmol/l (80–110 mg/dl)
No change in dose (target)
<4.4 mmol/l (<80 mg/dl)
-3 units
*Self-Monitored Plasma Glucose
When Levemir is used as part of a basal-bolus insulin regimen, Levemir should be administered once or twice daily depending on patients' needs. The dose of Levemir should be adjusted individually.
Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.
When adjusting dose in order to improve glucose control, patients should be advised to be aware of signs of hypoglycaemia.
Special populations
Elderly (≥65 years old)
Levemir can be used in elderly patients. In elderly patients, glucose monitoring should be intensified and the Levemir dose adjusted on an individual basis.
Renal and hepatic impairment
Renal or hepatic impairment may reduce the patient's insulin requirements.
In patients with renal or hepatic impairment, glucose monitoring should be intensified and the Levemir dose adjusted on an individual basis.
Paediatric population
Levemir can be used in adolescents and children from the age of 1 year (see section 5.1). When changing basal insulin to Levemir, dose reduction of basal and bolus insulin needs to be considered on an individual basis, in order to minimise the risk of hypoglycaemia (see section 4.4).
In children and adolescents, glucose monitoring should be intensified and the Levemir dose adjusted on an individual basis.
The safety and efficacy of Levemir in children below the age of 1 year have not been established. No data are available.
Transfer from other insulin medicinal products
When transferring from other intermediate or long-acting insulin medicinal products, adjustment of the dose and timing of administration may be necessary (see section 4.4).
Close glucose monitoring is recommended during the transfer and in the initial weeks thereafter (see section 4.4).
Concomitant antidiabetic treatment may need to be adjusted (dose and/or timing of oral antidiabetic medicinal products or concurrent short/rapid-acting insulin medicinal products).
Method of administration
Levemir is a long-acting insulin analogue used as a basal insulin. Levemir is for subcutaneous administration only. Levemir must not be administered intravenously, as it may result in severe hypoglycaemia. Intramuscular administration should also be avoided. Levemir is not to be used in insulin infusion pumps.
Levemir is administered subcutaneously by injection in the abdominal wall, the thigh, the upper arm, the deltoid region or the gluteal region. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see sections 4.4 and 4.8). The duration of action will vary according to the dose, injection site, blood flow, temperature and level of physical activity. The injection can be given at any time during the day, but at the same time each day. For patients who require twice daily dosing to optimise blood glucose control, the evening dose can be administered in the evening or at bedtime.
For detailed user instructions, please refer to the package leaflet.
Administration with FlexPen
Levemir FlexPen is a pre-filled pen (colour-coded) designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm. FlexPen delivers 1–60 units in increments of 1 unit. Levemir FlexPen is only suitable for subcutaneous injections. If administration by syringe is necessary, a vial should be used.
Hypersensitivity to the active substance or to any of the excipients (see section 6.1).
Before travelling between different time zones, the patient should seek the doctor's advice since this may mean that the patient has to take the insulin and meals at different times.
Hyperglycaemia
Inadequate dosing or discontinuation of treatment, especially in type 1 diabetes, may lead to hyperglycaemia and diabetic ketoacidosis. Usually the first symptoms of hyperglycaemia develop gradually over a period of hours or days. They include thirst, increased frequency of urination, nausea, vomiting, drowsiness, flushed dry skin, dry mouth, loss of appetite as well as acetone odour of breath. In type 1 diabetes, untreated hyperglycaemic events eventually lead to diabetic ketoacidosis, which is potentially lethal.
Hypoglycaemia
Omission of a meal or unplanned, strenuous physical exercise may lead to hypoglycaemia.
In children, care should be taken to match insulin doses (especially in basal-bolus regimens) with food intake and physical activities in order to minimise the risk of hypoglycaemia.
Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement. In case of hypoglycaemia or if hypoglycaemia is suspected, Levemir must not be injected. After stabilisation of the patient's blood glucose, adjustment of the dose should be considered (see sections 4.8 and 4.9).
Patients whose blood glucose control is greatly improved, e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia, and should be advised accordingly. Usual warning symptoms may disappear in patients with longstanding diabetes.
Concomitant illness, especially infections and feverish conditions, usually increases the patient's insulin requirements. Concomitant diseases in the kidney, liver or affecting the adrenal, pituitary or thyroid gland can require changes in insulin dose.
When patients are transferred between different types of insulin medicinal products, the early warning symptoms of hypoglycaemia may change or become less pronounced than those experienced with their previous insulin.
Transfer from other insulin medicinal products
Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type, origin (animal insulin, human insulin or insulin analogue) and/or method of manufacture (recombinant DNA versus animal source insulin) may result in the need for a change in dose. Patients transferred to Levemir from another type of insulin may require a change in dose from that used with their usual insulin medicinal products. If an adjustment is needed, it may occur with the first dose or during the first few weeks or months.
Injection site reactions
As with any insulin therapy, injection site reactions may occur and include pain, redness, hives, inflammation, bruising, swelling and itching. Continuous rotation of the injection site within a given area may help to reduce or prevent these reactions. Reactions usually resolve in a few days to a few weeks. On rare occasions, injection site reactions may require discontinuation of Levemir.
Skin and subcutaneous tissue disorders
Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site from an affected to an unaffected area, and dose adjustment of antidiabetic medications may be considered.
Hypoalbuminaemia
There are limited data in patients with severe hypoalbuminaemia. Careful monitoring is recommended in these patients.
Combination of Levemir with pioglitazone
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and Levemir is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.
Avoidance of accidental mix-ups/medication errors
Patients must be instructed to always check the insulin label before each injection to avoid accidental mix-ups between Levemir and other insulin products.
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
A number of medicinal products are known to interact with the glucose metabolism.
The following substances may reduce the patient's insulin requirements:
Oral antidiabetic medicinal products, GLP-1 receptor agonists, monoamine oxidase inhibitors (MAOI), beta-blockers, angiotensin converting enzyme (ACE) inhibitors, salicylates, anabolic steroids and sulphonamides.
The following substances may increase the patient's insulin requirements:
Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone and danazol.
Beta-blockers may mask the symptoms of hypoglycaemia.
Octreotide/lanreotide may either increase or decrease the insulin requirement.
Alcohol may intensify or reduce the hypoglycaemic effect of insulin.
Pregnancy
The use of Levemir in pregnant women with diabetes has been investigated in a clinical trial and in a prospective non-interventional post-authorisation safety study (see section 5.1). Post-marketing data in pregnant women using Levemir, with more than 4,500 pregnancy outcomes do not indicate any increased risk of malformative or feto/neonatal toxicity. Treatment with Levemir can be considered during pregnancy, if clinically needed.
In general, intensified blood glucose control and monitoring of pregnant women with diabetes are recommended throughout pregnancy and when contemplating pregnancy. Insulin requirements usually fall in the first trimester and increase subsequently during the second and third trimester. After delivery, insulin requirements normally return rapidly to pre-pregnancy values.
Breast-feeding
It is unknown whether insulin detemir is excreted in human milk. No metabolic effects of ingested insulin detemir on the breast-fed newborn/infant are anticipated since insulin detemir, as a peptide, is digested into amino acids in the human gastrointestinal tract.
Breast-feeding women may require adjustments in insulin dose and diet.
Fertility
Animal studies do not indicate harmful effects with respect to fertility.
The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).
Patients should be advised to take precautions to avoid hypoglycaemia while driving. This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.
Summary of the safety profile
Adverse reactions observed in patients using Levemir are mainly due to the pharmacologic effect of insulin. The overall percentage of treated patients expected to experience adverse reactions is estimated to be 12%.
The most frequently reported adverse reaction during treatment is hypoglycaemia, please see section 4.8, Description of selected adverse reactions.
From clinical investigations, it is known that major hypoglycaemia, defined as requirement for third party intervention, occurs in approximately 6% of the patients treated with Levemir.
Injection site reactions are seen more frequently during treatment with Levemir than with human insulin products. These reactions include pain, redness, hives, inflammation, bruising, swelling and itching at the injection site. Most of the injection site reactions are minor and of a transitory nature, i.e. they normally disappear during continued treatment in a few days to a few weeks.
At the beginning of the insulin treatment, refraction anomalies and oedema may occur; these reactions are usually of transitory nature. Fast improvement in blood glucose control may be associated with acute painful neuropathy, which is usually reversible. Intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy, while long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy.
Tabulated list of adverse reactions
Adverse reactions listed below are based on clinical trial data and classified according to MedDRA frequency and System Organ Class. Frequency categories are defined according to the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Immune system disorders
Uncommon – Allergic reactions, potentially allergic reactions, urticaria, rash, eruptions*
Very rare – Anaphylactic reactions*
Metabolism and nutrition disorders
Very common – Hypoglycaemia*
Nervous system disorders
Rare – Peripheral neuropathy (painful neuropathy)
Eye disorders
Uncommon – Refraction disorders
Uncommon – Diabetic retinopathy
Skin and subcutaneous tissue disorders
Uncommon – Lipodystrophy*
Not known – Cutaneous amyloidosis*†
General disorders and administration site conditions
Common – Injection site reactions
Uncommon – Oedema
* see section 4.8, Description of selected adverse reactions.
† ADR from postmarketing sources.
Description of selected adverse reactions
Allergic reactions, potentially allergic reactions, urticaria, rash, eruptions
Allergic reactions, potentially allergic reactions, urticaria, rash and eruptions are uncommon when Levemir is used in basal-bolus regimen. However, when used in combination with oral antidiabetic medicinal products, three clinical studies have shown a frequency of common (2.2% of allergic reactions and potentially allergic reactions have been observed).
Anaphylactic reactions
The occurrence of generalised hypersensitivity reactions (including generalised skin rash, itching, sweating, gastrointestinal upset, angioneurotic oedema, difficulties in breathing, palpitation and reduction in blood pressure) is very rare but can potentially be life threatening.
Hypoglycaemia
The most frequently reported adverse reaction is hypoglycaemia. It may occur if the insulin dose is too high in relation to the insulin requirement. Severe hypoglycaemia may lead to unconsciousness and/or convulsions and may result in temporary or permanent impairment of brain function or even death. The symptoms of hypoglycaemia usually occur suddenly. They may include cold sweats, cool pale skin, fatigue, nervousness or tremor, anxiousness, unusual tiredness or weakness, confusion, difficulty in concentrating, drowsiness, excessive hunger, vision changes, headache, nausea and palpitation.
Skin and subcutaneous tissue disorders
Lipodystrophy (including lipohypertrophy, lipoatrophy) and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).
Paediatric population
Based on post-marketing sources and clinical trials, the frequency, type and severity of adverse reactions observed in the paediatric population do not indicate any differences to the broader experience in the general diabetes population.
Other special populations
Based on post-marketing sources and clinical trials, the frequency, type and severity of adverse reactions observed in elderly patients and in patients with renal or hepatic impairment do not indicate any differences to the broader experience in the general population.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via
Great Britain
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
A specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if too high doses relative to the patient's requirement are administered:
• Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. It is therefore recommended that the diabetic patient always carries sugar-containing products.
• Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated with glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously by a trained person, or with glucose given intravenously by a healthcare professional. Glucose must be given intravenously, if the patient does not respond to glucagon within 10 to 15 minutes. Upon regaining consciousness, administration of oral carbohydrates is recommended for the patient in order to prevent a relapse.
Ask anything about Levemir FlexPen 100 units/ml solution for injection in pre-filled pen. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.